Clinical Trial

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)

Study acronym: REVEAL-2
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with chronic Thyroid Eye Disease (TED).
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2024-10-02; most recent amendment 2026-05-15.
Status change: Recruiting → Active, Not Recruiting 2025-09-24
Trial Details
NCT Number NCT06625398
Lead Sponsor Viridian Therapeutics, Inc.
Conditions Thyroid Eye Disease
Enrollment 204 participants
Start Date 2024-08-27
Primary Completion 2026-03-04 (estimated)
Study Completion 2026-12-15 (estimated)
Updated on ClinicalTrials.gov 2026-05-19